Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody.

[1]  J. Yewdell,et al.  MHC class I-associated peptides produced from endogenous gene products with vastly different efficiencies. , 1997, Journal of immunology.

[2]  C. Benoist,et al.  The role of CD8+ T cells in the initiation of insulin‐dependent diabetes mellitus , 1996, European journal of immunology.

[3]  P. Cresswell,et al.  Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP. , 1996, Immunity.

[4]  R. Germain,et al.  Partial signaling by CD8+ T cells in response to antagonist ligands , 1996, The Journal of experimental medicine.

[5]  Y. Chien,et al.  A TCR binds to antagonist ligands with lower affinities and faster dissociation rates than to agonists. , 1996, Immunity.

[6]  S. Jameson,et al.  T-cell-receptor affinity and thymocyte positive selection , 1996, Nature.

[7]  H. Eisen,et al.  Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. , 1996, Immunity.

[8]  P. S. Andersen,et al.  A recombinant antibody with the antigen-specific, major histocompatibility complex-restricted specificity of T cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[9]  P. Bruggen,et al.  Human tumor antigens recognized by T lymphocytes , 1996, The Journal of experimental medicine.

[10]  A. Rudensky,et al.  A study of complexes of class II invariant chain peptide: Major histocompatibility complex class II molecules using a new complex‐specific monoclonal antibody , 1996, European journal of immunology.

[11]  N. Shastri,et al.  A rare cryptic translation product is presented by Kb major histocompatibility complex class I molecule to alloreactive T cells , 1995, The Journal of experimental medicine.

[12]  A. G. Grandea,et al.  Dependence of Peptide Binding by MHC Class I Molecules on Their Interaction with TAP , 1995, Science.

[13]  R. Germain,et al.  Major histocompatibility complex class I presentation of peptides derived from soluble exogenous antigen by a subset of cells engaged in phagocytosis , 1995, The Journal of experimental medicine.

[14]  D. Margulies,et al.  Lack of strict correlation of functional sensitization with the apparent affinity of MHC/peptide complexes for the TCR. , 1995, Journal of immunology.

[15]  R. Anderson,et al.  Antigen processing in vivo and the elicitation of primary CTL responses. , 1995, Journal of immunology.

[16]  P. A. Peterson,et al.  Crystal structure of an H-2Kb-ovalbumin peptide complex reveals the interplay of primary and secondary anchor positions in the major histocompatibility complex binding groove. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Yewdell,et al.  Expression of adenovirus E3/19K protein does not alter mouse MHC class I-restricted responses to vaccinia virus. , 1994, Virology.

[18]  J. M. Kioschos,et al.  Presentation of a horse cytochrome c peptide by multiple H‐2b class I major histocompatibility complex (MHC) molecules to C57BL/6‐ and bm1‐derived cytotoxic T lymphocytes: Presence of a single MHC anchor residue may confer efficient peptide‐specific CTL recognition , 1994, European journal of immunology.

[19]  Young Sang Kim,et al.  T cell receptor-MHC class I peptide interactions: affinity, kinetics, and specificity. , 1994, Science.

[20]  R. J. Cohen,et al.  Kinetics and affinity of reactions between an antigen-specific T cell receptor and peptide-MHC complexes. , 1994, Immunity.

[21]  P. A. Peterson,et al.  Crystal structures of two viral peptides in complex with murine MHC class I H-2Kb. , 1994, Science.

[22]  Ronald N. Germain,et al.  MHC-dependent antigen processing and peptide presentation: Providing ligands for T lymphocyte activation , 1994, Cell.

[23]  M. Bevan,et al.  Peptide variants reveal how antibodies recognize major histocompatibility complex class I , 1993, European journal of immunology.

[24]  M. Bevan,et al.  Clone-specific T cell receptor antagonists of major histocompatibility complex class I-restricted cytotoxic T cells , 1993, The Journal of experimental medicine.

[25]  P. Kourilsky,et al.  Monoclonal antibodies directed against T cell epitopes presented by class I MHC antigens. , 1993, International immunology.

[26]  J. D. Dal Porto,et al.  Major histocompatibility complex conformational epitopes are peptide specific , 1992, The Journal of experimental medicine.

[27]  J. Bluestone,et al.  Peptide-induced conformational changes in class I heavy chains alter major histocompatibility complex recognition , 1992, The Journal of experimental medicine.

[28]  William S. Lane,et al.  Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size , 1992, Nature.

[29]  N. Shastri,et al.  Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[30]  A. Rudensky,et al.  Monoclonal antibody detection of a major self peptide. MHC class II complex. , 1992, Journal of immunology.

[31]  F. Oliveri,et al.  Specific low-affinity recognition of major histocompatibility complex plus peptide by soluble T-cell receptor , 1992, Nature.

[32]  R. Henderson,et al.  Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. , 1992, Science.

[33]  M. Bevan,et al.  Ham-2 corrects the class I antigen-processing defect in RMA-S cells , 1992, Nature.

[34]  M. Davis,et al.  Low affinity interaction of peptide-MHC complexes with T cell receptors. , 1991, Science.

[35]  Peter Walden,et al.  Exact prediction of a natural T cell epitope , 1991, European journal of immunology.

[36]  A. Rudensky,et al.  Sequence analysis of peptides bound to MHC class II molecules , 1991, Nature.

[37]  J. Monaco,et al.  Structural and serological similarity of MHC-linked LMP and proteasome (multicatalytic proteinase) complexes , 1991, Nature.

[38]  H. Rammensee,et al.  Identification of naturally processed viral nonapeptides allows their quantification in infected cells and suggests an allele-specific T cell epitope forecast , 1991, The Journal of experimental medicine.

[39]  M. Luscher,et al.  Peptide binding to class I MHC on living cells and quantitation of complexes required for CTL lysis , 1991, Nature.

[40]  R. Arnon,et al.  Immunomodulation of experimental allergic encephalomyelitis by antibodies to the antigen–Ia complex , 1991, Nature.

[41]  A. Vitiello,et al.  Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex , 1991, The Journal of experimental medicine.

[42]  H. Grey,et al.  The minimal number of class II MHC-antigen complexes needed for T cell activation. , 1990, Science.

[43]  Hidde L. Ploegh,et al.  Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro , 1990, Cell.

[44]  Emil R. Unanue,et al.  Quantitation of antigen-presenting cell MHC class II/peptide complexes necessary for T-cell stimulation , 1990, Nature.

[45]  J. Yewdell,et al.  The binary logic of antigen processing and presentation to T cells , 1990, Cell.

[46]  H. Ljunggren,et al.  Association of class I major histocompatibility heavy and light chains induced by viral peptides , 1989, Nature.

[47]  P. Parham,et al.  Cytotoxic T cell responses in HLA-A2.1 transgenic mice. Recognition of HLA alloantigens and utilization of HLA-A2.1 as a restriction element. , 1989, Journal of immunology.

[48]  M. Bevan,et al.  Introduction of soluble protein into the class I pathway of antigen processing and presentation , 1988, Cell.

[49]  B. Coupar,et al.  A general method for the construction of recombinant vaccinia viruses expressing multiple foreign genes. , 1988, Gene.

[50]  R. E. Cunningham,et al.  Cell growth cycle block of T cell hybridomas upon activation with antigen , 1987, The Journal of experimental medicine.

[51]  H. Ljunggren,et al.  Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism , 1985, The Journal of experimental medicine.

[52]  D Rodbard,et al.  Ligand: a versatile computerized approach for characterization of ligand-binding systems. , 1980, Analytical biochemistry.

[53]  A. Israël,et al.  The regulation and expression of MHC class I genes. , 1990, Immunology today.

[54]  E. Harlow,et al.  Antibodies: A Laboratory Manual , 1988 .

[55]  D. Cheresh,et al.  Human tumor antigens. , 1987, Advances in immunology.